Improving Mental Health Outcomes with Pharmacogenomics

Improved Genetic Profiling Techniques

The move from candidate polymorphisms to comprehensive sequencing is, in fact, a step change within pharmacogenomics. In comprehensive sequencing, it is, in principle, possible to scan for any genetic variations that may have an effect on drug response. It contributes to the identification of new genetic variants contributing to drug efficacy and toxicity and, hence, to hitherto unexplained variability.

Then came the realization that ethno-geographic diversity would be a factor to contend with in pharmacogenomics because genetic profiling would be refined. As the genetic markers are variable across populations, a tailored approach will help in recognizing the benefits of pharmacogenomics equally for all groups of patients. This step is quite important to address health inequities and to make pharmacogenomics progress inclusive of all.

Pharmacogenomics in Psychiatric Practice

The integration of pharmacogenomics into psychiatric practice, from genetic testing to result interpretation and application of knowledge gained in clinical decision-making, includes a few steps. Genetic testing typically comprises the analysis of DNA from a saliva or blood specimen to show the presence of certain gene variations related to drug metabolism. Results would, therefore, be useful in the choice of medications, dosages, and possible monitoring that may be necessary.

For example, polymorphisms in genes like CYP2D6 and CYP2C19 have a large effect on the metabolism of antidepressants and antipsychotics. Some variants may require decreased doses to avoid side effects; others require higher doses to achieve proper therapeutic levels. By applying pharmacogenomics information, clinicians can make more informed decisions that, perhaps, may shorten the time required to find an effective treatment and improve the overall patient outcome.

Real-World Applications and Challenges

While pharmacogenomics undoubtedly offers significant potential for benefiting patients, there are problems with how it can be practically implemented. First of all, large studies are needed to replicate clinical validity in different populations and settings. Moreover, genetic testing may be expensive, and sufficient access may not be available. Multiple current efforts are already working to overcome these challenges through research aimed at establishing the cost-effectiveness and clinical benefits of pharmacogenomics.

Real-world applications of pharmacogenomics have already had some positive results. For example, the usage of pharmacogenomics testing within the management of treatment-resistant depression has shown that with the test, some are more likely to benefit from specific antidepressants than without it. This also improves treatment efficacy and reduces the incidence of adverse drug reactions, one major concern in psychiatric care.

The Future of Pharmacogenomics in Mental Health

With continued research and technological advances being made, the future looks promising for pharmacogenomics in mental health, which is changing toward greater personalization of treatments. Provided that the knowledge of the genetic basis of drug responses continues to progress, it is likely that a time will soon come when pharmacogenomics testing will be part of standard mental health care. Researchers and clinicians will have to collaborate with policymakers to ensure that the benefits of pharmacogenomics are translated for all patients.

One of the exciting developments in this area is the potential role of pharmacogenomics in guiding the use of combination therapies for the treatment of mental health. An understanding of the genetic determinants of response to multiple medications could give the clinician the opportunity to work out more efficient treatment regimens with reduced risk of adverse effects and increased therapeutic benefits. This might be especially useful for patients with complex or treatment-resistant conditions.

Conclusion

It has the potential to revolutionize mental health treatment with individualized treatment strategies and improve outcomes for patients, reducing the burden of trial-and-error prescribing. Yet, even against the backdrop of existing challenges to its implementation, the body of evidence on the clinical utility of pharmacogenomics testing is large and growing; it underlines its importance in modern psychiatric practice. 

Pharmacogenomics is rapidly growing and, indeed, forms one of the pillars of individualized medicine in mental health. It would give much-needed hope for more effective and customized treatment possibilities to patients from across the world.

References

1. Brown LC, Stanton JD, Bharthi K, Maruf AA, Müller DJ, Bousman CA. Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials. Clin Pharmacol Ther. 2022 Dec;112(6):1303-1317. doi: 10.1002/cpt.2748. Epub 2022 Oct 11. PMID: 36111494; PMCID: PMC9827897.
2. Zhou Y, Koutsilieri S, Eliasson E, Lauschke VM. A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing. Basic Clin Pharmacol Toxicol. 2022 Dec;131(6):452-464. doi: 10.1111/bcpt.13779. Epub 2022 Aug 22. PMID: 35971800; PMCID: PMC9805052.
3. Amezcua L, Rivera VM, Vazquez TC, Baezconde-Garbanati L, Langer-Gould A. Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US: A Review. JAMA Neurol. 2021 Dec 1;78(12):1515-1524. doi: 10.1001/jamaneurol.2021.3416. PMID: 34605866.
4. Tewkesbury DH, Robey RC, Barry PJ. Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy. Breathe (Sheff). 2021 Dec;17(4):210112. doi: 10.1183/20734735.0112-2021. PMID: 35035569; PMCID: PMC8753614.
5. Lima JJ, Thomas CD, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DL, Scott SA, Schwab M, Uppugunduri CRS, Formea CM, Franciosi JP, Sangkuhl K, Gaedigk A, Klein TE, Gammal RS, Furuta T. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021 Jun;109(6):1417-1423. doi: 10.1002/cpt.2015. Epub 2020 Sep 20. PMID: 32770672; PMCID: PMC7868475.
6. van der Lee M, Allard WG, Vossen RHAM, Baak-Pablo RF, Menafra R, Deiman BALM, Deenen MJ, Neven P, Johansson I, Gastaldello S, Ingelman-Sundberg M, Guchelaar HJ, Swen JJ, Anvar SY. Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data. Sci Transl Med. 2021 Jul 21;13(603):eabf3637. doi: 10.1126/scitranslmed.abf3637. PMID: 34290055.
7. Sun L, Pennells L, Kaptoge S, Nelson CP, Ritchie SC, Abraham G, Arnold M, Bell S, Bolton T, Burgess S, Dudbridge F, Guo Q, Sofianopoulou E, Stevens D, Thompson JR, Butterworth AS, Wood A, Danesh J, Samani NJ, Inouye M, Di Angelantonio E. Polygenic risk scores in cardiovascular risk prediction: A cohort study and modelling analyses. PLoS Med. 2021 Jan 14;18(1):e1003498. doi: 10.1371/journal.pmed.1003498. PMID: 33444330; PMCID: PMC7808664.
8. Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. Clin Pharmacol Ther. 2020 Jan;107(1):171-175. doi: 10.1002/cpt.1651. Epub 2019 Nov 5. PMID: 31562822; PMCID: PMC6925644.

   Top Experts on “pharmacogenomics“

   C. Sander

   H-Index: 152

   Publication Count: 480

   Citation Count: 189519

   Affiliation: Department of Computational Biology, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA.

   P. Tak

   H-Index: 116

   Publication Count: 763

   Citation Count: 61422

   Affiliation: Department of Clinical Immunology & Rheumatology, Academic Medical Centre, Amsterdam University Medical Centre, Amsterdam, Netherlands.

   D. Nebert

   H-Index: 112

   Publication Count: 561

   Citation Count: 52038

   Affiliation: Department of Environmental Health and Center for Environmental Genetics, University of Cincinnati Medical Center, Cincinnati, OH, 45267-0056, USA.

   W. Figg

   H-Index: 105

   Publication Count: 922

   Citation Count: 38310

   Affiliation: Clinical Pharmacology Program, CCR, National Cancer Institute, NIH, 9000 Rockville Pike, Building 10, Room 5A01, Bethesda, MD, 20892, USA.

   L. Einhorn

   H-Index: 103

   Publication Count: 780

   Citation Count: 39670

   Affiliation: Hematology and Oncology, Indiana University Melvin and Bren Simon Cancer Center, 535 Barnhill Drive, RT 473, Indianapolis, IN, 46202, USA.

   M. Pirmohamed

   H-Index: 102

   Publication Count: 931

   Citation Count: 45488

   Affiliation: MRC Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3GL, United Kingdom; email:

   R. Altman

   H-Index: 95

   Publication Count: 649

   Citation Count: 42205

   Affiliation: Departments of Medicine, Genetics, Bioengineering, and Biomedical Data Science, Stanford University, Stanford, CA, USA.

   R. Weinshilboum

   H-Index: 94

   Publication Count: 686

   Citation Count: 36677

   Affiliation: Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, United States.

   M. Ratain

   H-Index: 88

   Publication Count: 796

   Citation Count: 36156

   Affiliation: Department of Medicine, Center for Personalized Therapeutics, Committee on Clinical Pharmacology and Pharmacogenomics, and Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois.

   A. Daly

   H-Index: 84

   Publication Count: 427

   Citation Count: 27793

   Affiliation: Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.

   Find experts on any field